Page 2 - Conditionally Active Biologic News Today

SAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...

/PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB)...

SAN DIEGO, Dec. 21, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic antibody therapeutics, today... | December 21, 2021

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Share this article Share this article SAN DIEGO, Feb. 22, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced the publication by Proceedings of the National Academy of Sciences (PNAS) that describes the design and functionality of therapeutic antibody candidates utilizing BioAtlas proprietary CAB technology making them active only in the acidic tumor microenviro...

Share this article Share this article SAN DIEGO, Jan. 8, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that Jay M. Short, Ph.D., Chief Executive Officer, and Scott Smith, President, with participation by other BioAtla executives, will present at the 39 th Annual J.P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021, at 2:50 PM Eastern Time...